Brief: Keros Therapeutics Announces Effectiveness Of Global License Agreement With Takeda
21/01/2025 13:31
Jan 21 (Reuters) - Takeda Pharmaceutical Co Ltd
4502.T :
* KEROS THERAPEUTICS ANNOUNCES EFFECTIVENESS OF GLOBAL
LICENSE
AGREEMENT WITH TAKEDA TO ADVANCE ELRITERCEPT
* KEROS THERAPEUTICS INC - TAKEDA TO MAKE $200 MILLION
UPFRONT
PAYMENT TO CO IN CONNECTION WITH EFFECTIVENESS OF AGREEMENT
Source text: ID:nGNX9LF9Dy
Further company coverage: 4502.T
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops